Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer. The Oncologist
Subscribe to Our Newsletter
You are leaving this research use-only area
You are about to access content intended for a different region. Information, regulatory status, and product availability may vary by location.
